(Q37523971)

20 August 2017

1 reference

title

Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators (English)

1 reference

20 August 2017

1 reference

Pernille Nordly

1

1 reference

20 August 2017

Henriette Baun Madsen

series ordinal

2

1 reference

20 August 2017

Hanne Moerck Nielsen

series ordinal

3

1 reference

20 August 2017

Camilla Foged

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Expert Opinion on Drug Delivery

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

657-672

1 reference

Vaccine immunopotentiators of the future

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Approaching the asymptote? Evolution and revolution in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Maturation, activation, and protection of dendritic cells induced by double-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Decoding the patterns of self and nonself by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The role of Toll-like receptors and Nod proteins in bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

THE EVOLUTION OF ADAPTIVE IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Th17: an effector CD4 T cell lineage with regulatory T cell ties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Cell-mediated cytotoxic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Signals and signs for lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Immunology taught by viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Vaccine entrapment in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

ISCOMs (immunostimulating complexes): the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

ISCOMs and other saponin based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

In vivo activity of cationic immune stimulating complexes (PLUSCOMs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

ISCOMATRIX adjuvant for antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The perfect mix: recent progress in adjuvant research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Structure and function of Toll receptors and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

ESAT-6 subunit vaccination against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Recent advances with TLR2-targeting lipopeptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Immunological concepts of vaccine adjuvant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Adjuvants--a classification and review of their modes of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Recent developments in adjuvants for vaccines against infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Pathogen recognition and development of particulate vaccines: does size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Cytokines as potential vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Natural adjuvants: endogenous activators of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Action of saponin on biological cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Intranasal immunization of mice with Echinococcus granulosus surface antigens iscoms evokes a strong immune response, biased towards glucidic epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Recent advances in the discovery and delivery of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

Innate and adaptive immunity: specificities and signaling hierarchies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425240903018863

10.1517/17425240903018863

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference